Gabelli Comments on Incyte Co.’s FY2020 Earnings (INCY)

Incyte Co. (NASDAQ:INCY) – Analysts at Gabelli boosted their FY2020 earnings per share (EPS) estimates for Incyte in a research note issued on Wednesday. Gabelli analyst J. He now forecasts that the biopharmaceutical company will post earnings of $4.35 per share for the year, up from their prior forecast of $4.30.

Other equities analysts also recently issued research reports about the company. TheStreet downgraded Incyte from a “c-” rating to a “d+” rating in a research report on Tuesday, December 5th. BMO Capital Markets upped their target price on Incyte from $162.00 to $166.00 and gave the company an “outperform” rating in a research report on Tuesday, October 31st. Royal Bank of Canada cut their price target on Incyte from $136.00 to $120.00 and set a “sector perform” rating for the company in a research note on Tuesday, November 21st. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Incyte in a research note on Tuesday, October 31st. Finally, Citigroup reiterated a “market perform” rating and issued a $120.00 price target (down from $135.00) on shares of Incyte in a research note on Tuesday, January 2nd. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $143.71.

Incyte (NASDAQ INCY) traded up $1.24 during trading on Friday, hitting $93.16. The stock had a trading volume of 1,912,640 shares, compared to its average volume of 1,412,143. Incyte has a 52 week low of $88.81 and a 52 week high of $153.15. The company has a quick ratio of 4.81, a current ratio of 4.82 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $19,398.55, a P/E ratio of -116.45 and a beta of 0.74.

Incyte (NASDAQ:INCY) last posted its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.17 EPS for the quarter, beating the consensus estimate of $0.06 by $0.11. Incyte had a negative return on equity of 12.91% and a negative net margin of 10.90%. The company had revenue of $381.50 million for the quarter, compared to the consensus estimate of $360.34 million. During the same quarter in the prior year, the business earned $0.19 earnings per share. The firm’s revenue for the quarter was up 41.6% on a year-over-year basis.

In other Incyte news, Director Paul A. Friedman sold 28,507 shares of the company’s stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $105.24, for a total transaction of $3,000,076.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider David W. Gryska sold 6,760 shares of the company’s stock in a transaction on Friday, January 5th. The stock was sold at an average price of $98.87, for a total value of $668,361.20. Following the sale, the insider now owns 20,752 shares of the company’s stock, valued at $2,051,750.24. The disclosure for this sale can be found here. Insiders have sold 44,878 shares of company stock valued at $4,636,494 over the last 90 days. Corporate insiders own 17.70% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in INCY. Vanguard Group Inc. lifted its stake in Incyte by 11.1% during the second quarter. Vanguard Group Inc. now owns 17,125,542 shares of the biopharmaceutical company’s stock worth $2,156,276,000 after purchasing an additional 1,709,685 shares during the last quarter. Manning & Napier Advisors LLC bought a new stake in Incyte during the third quarter worth $125,065,000. Janus Henderson Group PLC lifted its stake in Incyte by 4,570.1% during the second quarter. Janus Henderson Group PLC now owns 1,045,363 shares of the biopharmaceutical company’s stock worth $131,622,000 after purchasing an additional 1,022,979 shares during the last quarter. Old Mutual Global Investors UK Ltd. lifted its stake in Incyte by 374.4% during the third quarter. Old Mutual Global Investors UK Ltd. now owns 930,319 shares of the biopharmaceutical company’s stock worth $108,605,000 after purchasing an additional 734,235 shares during the last quarter. Finally, Matrix Capital Management Company LP lifted its stake in Incyte by 28.3% during the second quarter. Matrix Capital Management Company LP now owns 1,796,716 shares of the biopharmaceutical company’s stock worth $226,225,000 after purchasing an additional 396,716 shares during the last quarter. Hedge funds and other institutional investors own 90.76% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/01/20/gabelli-comments-on-incyte-co-s-fy2020-earnings-incy.html.

Incyte Company Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Earnings History and Estimates for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply